Medicine Recommendations

Pain.

Metabolic acidosis and for maintenance treatment against recurrence of metabolic acidosis in adults with chronic renal impairment.

Prevention and treatment of ischaemia following subarachnoid haemorrhage

Treating COVID-19 (NICE TA878)

NICE TA878 - Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Depressive illness

Chronic Neuropathic Pain

Bowel obstruction - GI secretions associated with bowel obstruction. 

Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)

Unlicensed use for orthostatic intolerance disorders e.g. postural orthostatic tachycardia syndrome (PoTS)

Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)

Treatment and prophylaxis of schizophrenia

Tablets, orodispersible tablets, powder for solution for injection

Nausea and vomiting, appetite stimulant.

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquilization

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

COPD

Adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.

Chronic spontaneous urticaria (NICE TA339)

NICE TA339 - Omalizumab for previously treated chronic spontaneous urticaria

Severe chronic inducible urticarias

For preterm birth risk reduction